Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07494-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neurological Sciences, 2024. Verfasst von Luca Gentile und 26 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hereditary transthyretin (ATTRv, v for variant) amyloidosis with polyneuropathy is a rare disease caused by mutations in the transthyretin gene. In ATTRv amyloidosis, multisystem extracellular deposits of amyloid cause tissue and organ dysfunction. Patisiran is a small interfering RNA molecule drug that reduces circulating levels of mutant and wild-type TTR proteins. Prior to its regulatory approval, patisiran was available in Italy through a compassionate use programme (CUP). The aim of this study was to analyse the long-term outcomes of patients who entered into the CUP.
Methods
This was a multicentre, observational, retrospective study of patients with ATTRv amyloidosis treated with patisiran. The analysis included change from baseline to 12, 24, 36 and 48 months in familial amyloid polyneuropathy (FAP) stage, polyneuropathy disability (PND) class, neuropathy impairment score (NIS), modified body mass index (mBMI), Compound Autonomic Dysfunction Test (CADT), Karnofsky Performance Status (KPS) scale and Norfolk Quality of Life–Diabetic Neuropathy (QoL-DN) questionnaire. Safety data were also analysed.
Results
Forty patients from 11 Italian centres were enrolled: 23 in FAP 1 (6 in PND 1 and 17 in PND 2) and 17 in FAP 2 (8 in PND 3a and 9 in PND 3b) stage. In this population, the mean NIS at baseline was 71.4 (± 27.8); mBMI, 917.1 (± 207) kg/m 2 ; KPS, 67.1 (± 14.0); Norfolk QoL-DN, 62.2 (± 25.2); and CADT, 13.2 (± 3.3). Statistical analysis showed few significant differences from baseline denoting disease stability. No new safety signals emerged.
Conclusions
Patisiran largely stabilised disease in patients with ATTRv amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- Department of Neurosciences, Neurology Unit, University of Padova, Padua, Italy.
- Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
- Department of Neurological Sciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
- Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy.
- IRCCS Policlinico San Martino Hospital, Genoa, Italy.
Zitieren
APA
Gentile, L., Mazzeo, A., Briani, C., Casagrande, S., De Luca, M., Fabrizi, G. M., Gagliardi, C., Gemelli, C., Forcina, F., Grandis, M., Guglielmino, V., Iabichella, G., Leonardi, L., Lozza, A., Manganelli, F., Mussinelli, R., My, F., Occhipinti, G., Fenu, S., …, & Luigetti, M. (2024). Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy. Neurological Sciences. https://doi.org/10.1007/s10072-024-07494-9
Vancouver
Gentile L, Mazzeo A, Briani C, Casagrande S, De Luca M, Fabrizi GM, et al. Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy. Neurological Sciences. 2024. doi:10.1007/s10072-024-07494-9
BibTeX
@article{Gentile2024,
author = {Gentile, Luca and Mazzeo, Anna and Briani, Chiara and Casagrande, Silvia and De Luca, Marcella and Fabrizi, Gian Maria and Gagliardi, Christian and Gemelli, Chiara and Forcina, Francesca and Grandis, Marina and Guglielmino, Valeria and Iabichella, Giacomo and Leonardi, Luca and Lozza, Alessandro and Manganelli, Fiore and Mussinelli, Roberta and My, Filomena and Occhipinti, Giuseppe and Fenu, Silvia and Russo, Massimo and Romano, Angela and Salvalaggio, Alessandro and Tagliapietra, Matteo and Tozza, Stefano and Palladini, Giovanni and Obici, Laura and Luigetti, Marco},
title = {Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07494-9}
}
EUVIMED